Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2003 Jun;77(11):6580–6584. doi: 10.1128/JVI.77.11.6580-6584.2003

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2003, American Society for Microbiology

PMC Copyright notice

FIG. 2. — Antibody treatment and respiratory rates. (A) BALB/c mice were i.v. treated with purified RSV G glycoprotein (G100) following i.p. administration of either PBS (G100/PBS) or anti-G glycoprotein (G100/anti-G) or anti-F glycoprotein monoclonal antibody (G100/anti-F). ⋆, significant differences (P < 0.05) compared with G100/PBS-treated group. (B) BALB/c mice were i.v. treated with purified RSV G glycoprotein (G100) following i.p. administration of either PBS (G100/PBS) or anti-SP monoclonal antibody (G100/anti-SP). ⋆, significant differences (P < 0.05) compared with G100/PBS-treated group. (C) BALB/c mice were i.v. treated with purified RSV G glycoprotein (G100) following i.p. administration of either PBS (G100/PBS) or anti-CX3CR1 monoclonal antibody (G100/anti-CX3CR1). ⋆, significant differences (P < 0.05) compared with G100/PBS-treated group. The mean respiratory rates ± standard errors from eight individual BALB/c mice were determined at time points between 0.25 and 4 h posttreatment.

FIG. 2. — Antibody treatment and respiratory rates. (A) BALB/c mice were i.v. treated with purified RSV G glycoprotein (G100) following i.p. administration of either PBS (G100/PBS) or anti-G glycoprotein (G100/anti-G) or anti-F glycoprotein monoclonal antibody (G100/anti-F). ⋆, significant differences (P < 0.05) compared with G100/PBS-treated group. (B) BALB/c mice were i.v. treated with purified RSV G glycoprotein (G100) following i.p. administration of either PBS (G100/PBS) or anti-SP monoclonal antibody (G100/anti-SP). ⋆, significant differences (P < 0.05) compared with G100/PBS-treated group. (C) BALB/c mice were i.v. treated with purified RSV G glycoprotein (G100) following i.p. administration of either PBS (G100/PBS) or anti-CX3CR1 monoclonal antibody (G100/anti-CX3CR1). ⋆, significant differences (P < 0.05) compared with G100/PBS-treated group. The mean respiratory rates ± standard errors from eight individual BALB/c mice were determined at time points between 0.25 and 4 h posttreatment.